GDTC · CIK 0001873093
CytoMed Therapeutics Limited
Annual figures as reported, FY2019–FY2025. Ratios and growth rates derived on-page.
Pharmaceutical Preparations
Company profile
Revenue
SGD 324K
▲ +366.7% vs FY2024
Net income
−SGD 4.0M
▼ −58.5% vs FY2024
Free cash flow
−SGD 4.3M
▼ −5.5% vs FY2024
Diluted EPS
−SGD 0.34
▼ −54.5% vs FY2024
Revenue
Annual, as reported
Net income
Losses shown in terracotta
Profitability & returns
quality of earningsMargins
Share of revenue kept at each line
Returns on capital
Net income vs year-end equity and assets
Return on equityReturn on assets
Cash flow
cash generationFree cash flow
Operating cash flow less capital expenditure
Operating cash flow
Net cash from operations
Shareholder returns
capital allocationDiluted shares outstanding
Falling count means buybacks outpace dilution
Balance sheet
financial positionStockholders’ equity
At fiscal year end
Net debt
Long-term debt less cash — negative means net cash
Growth rates
compounding, annualizedShare count change (split-adjusted)
+97.5%
5y
Key ratios
derived per fiscal year| Fiscal year | Net margin | FCF margin | ROE | ROA | Current ratio | Debt / equity |
|---|---|---|---|---|---|---|
| FY2025 | −1232.0% | −1336.5% | −58.3% | −50.0% | 5.17× | 0.06× |
| FY2024 | −3628.5% | −5913.8% | −27.9% | −25.0% | 9.89× | 0.05× |
| FY2023 | — | — | −36.8% | −33.4% | 14.08× | 0.04× |
| FY2022 | — | — | −534.1% | −59.9% | 0.60× | 1.37× |
| FY2021 | — | — | −79.2% | −33.7% | 1.12× | 0.36× |
| FY2020 | — | — | −406.8% | — | — | — |
| FY2019 | — | — | — | — | — | — |
Annual figures
as reported| Fiscal year | Revenue | Gross profit | Op. income | Net income | Diluted EPS | Op. cash flow | Capex | Total assets | Liabilities | Equity | Cash | LT debt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 | SGD 324K | — | — | −SGD 4.0M | −SGD 0.34 | −SGD 3.7M | SGD 638K | SGD 8.0M | SGD 1.1M | SGD 6.9M | SGD 2.1M | SGD 410K |
| FY2024 | SGD 70K | — | — | −SGD 2.5M | −SGD 0.22 | −SGD 2.7M | SGD 1.4M | SGD 10.1M | SGD 1.0M | SGD 9.0M | SGD 4.7M | SGD 432K |
| FY2023 | — | — | — | −SGD 4.1M | −SGD 0.39 | −SGD 3.5M | SGD 58K | SGD 12.4M | SGD 1.1M | SGD 11.2M | SGD 6.2M | SGD 442K |
| FY2022 | — | — | — | −SGD 3.1M | −SGD 0.40 | −SGD 1.4M | SGD 474K | SGD 5.2M | SGD 4.6M | SGD 586K | SGD 1.6M | SGD 804K |
| FY2021 | — | — | — | −SGD 2.1M | −SGD 0.30 | −SGD 1.7M | SGD 582K | SGD 6.1M | SGD 3.5M | SGD 2.6M | SGD 2.5M | SGD 925K |
| FY2020 | — | — | — | −SGD 1.9M | −SGD 0.33 | −SGD 849K | SGD 245K | — | — | SGD 476K | SGD 885K | — |
| FY2019 | — | — | — | — | — | — | — | — | — | SGD 1.9M | SGD 371K | — |
Latest filings
the most recent regulatory filings6-KForeign issuer report2026-06-23 ↗4Insider ownership filing2026-06-15 ↗6-KForeign issuer report2026-06-03 ↗3Insider ownership filing2026-05-26 ↗3Insider ownership filing2026-05-15 ↗3Insider ownership filing2026-05-15 ↗3Insider ownership filing2026-05-15 ↗3Insider ownership filing2026-05-15 ↗3Insider ownership filing2026-05-15 ↗6-KForeign issuer report2026-05-15 ↗
Company logos by Elbstream and unavatar.
All third-party trademarks, service marks, logos, and brand names used on this site are the property of their respective owners. The use of these logos is for identification and illustrative purposes only and does not imply any affiliation, sponsorship, or endorsement by the respective owners.